DNA origami as a carrier for circumvention of drug resistance.
Although a multitude of promising anti-cancer drugs have been developed over the past 50 years, effective delivery of the drugs to diseased cells remains a challenge. Recently, nanoparticles have been used as drug delivery vehicles due to their high delivery efficiencies and the possibility to circumvent cellular drug resistance. However, the lack of biocompatibility and inability to engineer spatially addressable surfaces for multi-functional activity remains an obstacle to their widespread use. Here we present a novel drug carrier system based on self-assembled, spatially addressable DNA origami nanostructures that confronts these limitations. Doxorubicin, a well-known anti-cancer drug, was non-covalently attached to DNA origami nanostructures through intercalation. A high level of drug loading efficiency was achieved, and the complex exhibited prominent cytotoxicity not only to regular human breast adenocarcinoma cancer cells (MCF 7), but more importantly to doxorubicin-resistant cancer cells, inducing a remarkable reversal of phenotype resistance. With the DNA origami drug delivery vehicles, the cellular internalization of doxorubicin was increased, which contributed to the significant enhancement of cell-killing activity to doxorubicin-resistant MCF 7 cells. Presumably, the activity of doxorubicin-loaded DNA origami inhibits lysosomal acidification, resulting in cellular redistribution of the drug to action sites. Our results suggest that DNA origami has immense potential as an efficient, biocompatible drug carrier and delivery vehicle in the treatment of cancer.
National Center for NanoScience and Technology, 11 BeiYiTiao, ZhongGuanCun, 100190 Beijing, China.
Qiao
Q
Jiang
Chen
C
Song
Jeanette
J
Nangreave
Xiaowei
X
Liu
Lin
L
Lin
Dengli
D
Qiu
Zhen-Gang
ZG
Wang
Guozhang
G
Zou
Xingjie
X
Liang
Hao
H
Yan
Baoquan
B
Ding
D000970:Antineoplastic Agents / Q000737:chemistry*; D001943:Breast Neoplasms / Q000188:drug therapy; D018736:DNA Adducts / Q000737:chemistry*; D004317:Doxorubicin / Q000737:chemistry*; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry*
D000970:Antineoplastic Agents; D018736:DNA Adducts; C031902:doxorubicin-DNA; D004317:Doxorubicin